中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 41 Issue 2
Feb.  2025
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(2): 365-369

New insights and prospects of drug-induced liver injury in the context of chronic cholestatic liver diseases

DOI: 10.12449/JCH250225
  • 1.

    Department of Traditional Chinese Medicine for Liver Diseases，The Fifth Medical Center of Chinese PLA General Hospital，Beijing 100039，China

  • 2.

    School of Traditional Chinese Medicine，Capital Medical University，Beijing 100069，China

Research funding:

China Medical Education Association, Major Scientific and Technological Challenges and Medical Technology Issues (2020KTY001);

General Project of National Natural Science Foundation of China (81673806)

More Information
  • Corresponding author: WANG Ruilin， WRL7905@163.com （ORCID： 0000-0002-7129-016X）
  • Received Date: 2024-05-30
  • Accepted Date: 2024-07-22
  • Published Date: 2025-02-25
    Abstract
  • Patients with chronic cholestatic liver diseases face numerous challenges in the detection， assessment， and management of suspected drug-induced liver injury （DILI）， and in particular， it is difficult to distinguish cholestatic DILI from the progression of underlying cholestatic liver diseases clinically and histologically. Currently， there is a lack of related research and management guidelines for DILI with chronic cholestatic liver diseases. This article discusses the potential risks， causality， and classification criteria for chronic cholestatic liver diseases with DILI， in order to improve the understanding of such diseases among clinicians and provide a reference for prevention， treatment， and management strategies.

     

    • FullText(HTML)
    • References(52)
  • [1]
    YU YC, MAO YM, CHEN CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury[J]. Hepatol Int, 2017, 11( 3): 221- 241. DOI: 10.1007/s12072-017-9793-2.
    [2]
    BJÖRNSSON ES, BERGMANN OM, BJÖRNSSON HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013, 144( 7): 1419- 1425. DOI: 10.1053/j.gastro.2013.02.006.
    [3]
    SGRO C, CLINARD F, OUAZIR K, et al. Incidence of drug-induced hepatic injuries: A French population-based study[J]. Hepatology, 2002, 36( 2): 451- 455. DOI: 10.1053/jhep.2002.34857.
    [4]
    SHEN T, LIU YX, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156( 8): 2230- 2241. e 11. DOI: 10.1053/j.gastro.2019.02.002.
    [5]
    CHALASANI N, BONKOVSKY HL, FONTANA R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study[J]. Gastroenterology, 2015, 148( 7): 1340- 1352. e 7. DOI: 10.1053/j.gastro.2015.03.006.
    [6]
    LICATA A, MINISSALE MG, CALVARUSO V, et al. A focus on epidemiology of drug-induced liver injury: Analysis of a prospective cohort[J]. Eur Rev Med Pharmacol Sci, 2017, 21( 1 Suppl): 112- 121.
    [7]
    CHALASANI N, FONTANA RJ, BONKOVSKY HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States[J]. Gastroenterology, 2008, 135( 6): 1924- 1934. e1- e4. DOI: 10.1053/j.gastro.2008.09.011.
    [8]
    BJORNSSON ES, JONASSON JG. Drug-induced cholestasis[J]. Clin Liver Dis, 2013, 17( 2): 191- 209. DOI: 10.1016/j.cld.2012.11.002.
    [9]
    LAMMERT C, IMLER T, TEAL E, et al. Patients with chronic liver disease suggestive of nonalcoholic fatty liver disease may be at higher risk for drug-induced liver injury[J]. Clin Gastroenterol Hepatol, 2019, 17( 13): 2814- 2815. DOI: 10.1016/j.cgh.2018.12.013.
    [10]
    BESSONE F, DIRCHWOLF M, RODIL MA, et al. Review article: Drug-induced liver injury in the context of nonalcoholic fatty liver disease-a physiopathological and clinical integrated view[J]. Aliment Pharmacol Ther, 2018, 48( 9): 892- 913. DOI: 10.1111/apt.14952.
    [11]
    CHALASANI N, ALJADHEY H, KESTERSON J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity[J]. Gastroenterology, 2004, 126( 5): 1287- 1292. DOI: 10.1053/j.gastro.2004.02.015.
    [12]
    RUSSO MW, HOOFNAGLE JH, GU JZ, et al. Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network[J]. Hepatology, 2014, 60( 2): 679- 686. DOI: 10.1002/hep.27157.
    [13]
    WATKINS PB, SELIGMAN PJ, PEARS JS, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury[J]. Hepatology, 2008, 48( 5): 1680- 1689. DOI: 10.1002/hep.22633.
    [14]
    FONTANA RJ, HAYASHI PH, BARNHART H, et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury[J]. Am J Gastroenterol, 2015, 110( 10): 1450- 1459. DOI: 10.1038/ajg.2015.283.
    [15]
    BJÖRNSSON E, DAVIDSDOTTIR L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice[J]. J Hepatol, 2009, 50( 3): 511- 517. DOI: 10.1016/j.jhep.2008.10.021.
    [16]
    YOKODA RT, RODRIGUEZ EA. Review: Pathogenesis of cholestatic liver diseases[J]. World J Hepatol, 2020, 12( 8): 423- 435. DOI: 10.4254/wjh.v12.i8.423.
    [17]
    Chinese Society of Hepatology, Chinese Medical Association. Guideline on the management of cholestasis liver diseases[J]. J Clin Hepatol, 2022, 38( 1): 62- 69.

    中华医学会肝病学分会. 胆汁淤积性肝病管理指南(2021年)[J]. 临床肝胆病杂志, 2022, 38( 1): 62- 69.
    [18]
    GOSSARD AA, TALWALKAR JA. Cholestatic liver disease[J]. Med Clin North Am, 2014, 98( 1): 73- 85. DOI: 10.1016/j.mcna.2013.09.002.
    [19]
    SARCOGNATO S, SACCHI D, GRILLO F, et al. Autoimmune biliary diseases: Primary biliary cholangitis and primary sclerosing cholangitis[J]. Pathologica, 2021, 113( 3): 170- 184. DOI: 10.32074/1591-951X-245.
    [20]
    PINZANI M, LUONG TV. Pathogenesis of biliary fibrosis[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864( 4 Pt B): 1279- 1283. DOI: 10.1016/j.bbadis.2017.07.026.
    [21]
    JANSEN PLM, GHALLAB A, VARTAK N, et al. The ascending pathophysiology of cholestatic liver disease[J]. Hepatology, 2017, 65( 2): 722- 738. DOI: 10.1002/hep.28965.
    [22]
    CHALASANI NP, MADDUR H, RUSSO MW, et al. ACG clinical guideline: Diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2021, 116( 5): 878- 898. DOI: 10.14309/ajg.0000000000001259.
    [23]
    BJÖRNSSON HK, BJÖRNSSON ES. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management[J]. Eur J Intern Med, 2022, 97: 26- 31. DOI: 10.1016/j.ejim.2021.10.035.
    [24]
    NORMAN BH. Drug induced liver injury(DILI). Mechanisms and medicinal chemistry avoidance/mitigation strategies[J]. J Med Chem, 2020, 63( 20): 11397- 11419. DOI: 10.1021/acs.jmedchem.0c00524.
    [25]
    LARREY D, ERLINGER S. Drug-induced cholestasis[J]. Baillieres Clin Gastroenterol, 1988, 2( 2): 423- 452. DOI: 10.1016/0950-3528(88)90010-3.
    [26]
    BESSONE F, HILLOTTE GL, AHUMADA N, et al. UDCA for drug-induced liver disease: Clinical and pathophysiological basis[J]. Semin Liver Dis, 2024, 44( 1): 1- 22. DOI: 10.1055/s-0044-1779520.
    [27]
    HU PF, WANG PQ, CHEN H, et al. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury[J]. J Dig Dis, 2016, 17( 9): 618- 627. DOI: 10.1111/1751-2980.12383.
    [28]
    HIRSCHFIELD GM, DYSON JK, ALEXANDER GJM, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines[J]. Gut, 2018, 67( 9): 1568- 1594. DOI: 10.1136/gutjnl-2017-315259.
    [29]
    FLOREANI A, de MARTIN S. Treatment of primary sclerosing cholangitis[J]. Dig Liver Dis, 2021, 53( 12): 1531- 1538. DOI: 10.1016/j.dld.2021.04.028.
    [30]
    ASCHENBRENNER DS. Excessive dosing of obeticholic acid may increase risk of liver damage[J]. Am J Nurs, 2018, 118( 2): 46. DOI: 10.1097/01.NAJ.0000530245.53335.c8.
    [31]
    U.S. Food and Drug Administration(FDA). FDA drug safety communication: FDA warns about serious liver injury with ocaliva(obeticholic acid) for rare chronic liver disease[EB/OL].[ 2024-05-30]. https://www.fda.gov/media/104801/download. https://www.fda.gov/media/104801/download
    [32]
    U.S. National Institutes of Health(NIH). LiverTox: Clinical and research information on drug-induced liver injury[EB/OL].[ 2024-05-30]. https://livertox.nlm.nih.gov. https://livertox.nlm.nih.gov
    [33]
    HIRSCHFIELD GM, MASON A, LUKETIC V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J]. Gastroenterology, 2015, 148( 4): 751- 761. e 8. DOI: 10.1053/j.gastro.2014.12.005.
    [34]
    KOWDLEY KV, LUKETIC V, CHAPMAN R, et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis[J]. Hepatology, 2018, 67( 5): 1890- 1902. DOI: 10.1002/hep.29569.
    [35]
    NEVENS F, ANDREONE P, MAZZELLA G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J]. N Engl J Med, 2016, 375( 7): 631- 643. DOI: 10.1056/NEJMoa1509840.
    [36]
    QUIGLEY G, AL ANI M, NADIR A. Occurrence of jaundice following simultaneous ursodeoxycholic acid cessation and obeticholic acid initiation[J]. Dig Dis Sci, 2018, 63( 2): 529- 532. DOI: 10.1007/s10620-017-4900-8.
    [37]
    HASEGAWA S, YONEDA M, KURITA Y, et al. Cholestatic liver disease: Current treatment strategies and new therapeutic agents[J]. Drugs, 2021, 81( 10): 1181- 1192. DOI: 10.1007/s40265-021-01545-7.
    [38]
    ZHANG JP. Pathological diagnosis of cholestatic liver disease[J]. J Clin Hepatol, 2024, 40( 6): 1093- 1099. DOI: 10.12449/JCH240605.

    张继平. 胆汁淤积性肝病的病理学诊断[J]. 临床肝胆病杂志, 2024, 40( 6): 1093- 1099. DOI: 10.12449/JCH240605.
    [39]
    BAI HH, FENG HJ, GUO LJ, et al. An analysis on the clinical biochemical and pathological characteristics of simple cholestatic type of drug induced liver injury[J]. Chin Hepatol, 2024, 29( 1): 37- 40, 55. DOI: 10.14000/j.cnki.issn.1008-1704.2024.01.011.

    白欢欢, 冯惠君, 郭立杰, 等. 单纯淤胆型药物性肝损伤临床生化及病理特点分析[J]. 肝脏, 2024, 29( 1): 37- 40, 55. DOI: 10.14000/j.cnki.issn.1008-1704.2024.01.011.
    [40]
    ALLISON R, GURAKA A, SHAWA IT, et al. Drug induced liver injury-a 2023 update[J]. J Toxicol Environ Health B Crit Rev, 2023, 26( 8): 442- 467. DOI: 10.1080/10937404.2023.2261848.
    [41]
    WEILER S, MERZ M, KULLAK-UBLICK GA. Drug-induced liver injury: The dawn of biomarkers?[J]. F1000Prime Rep, 2015, 7: 34. DOI: 10.12703/P7-34.
    [42]
    KWO PY, COHEN SM, LIM JK. ACG clinical guideline: Evaluation of abnormal liver chemistries[J]. Am J Gastroenterol, 2017, 112( 1): 18- 35. DOI: 10.1038/ajg.2016.517.
    [43]
    BJÖRNSSON E, TALWALKAR J, TREEPRASERTSUK S, et al. Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis[J]. Hepatology, 2010, 51( 6): 2040- 2048. DOI: 10.1002/hep.23588.
    [44]
    DELEMOS AS, FOUREAU DM, JACOBS C, et al. Drug-induced liver injury with autoimmune features[J]. Semin Liver Dis, 2014, 34( 2): 194- 204. DOI: 10.1055/s-0034-1375959.
    [45]
    SUZUKI A, BRUNT EM, KLEINER DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury[J]. Hepatology, 2011, 54( 3): 931- 939. DOI: 10.1002/hep.24481.
    [46]
    BÉNICHOU C. Criteria of drug-induced liver disorders. Report of an international consensus meeting[J]. J Hepatol, 1990, 11( 2): 272- 276. DOI: 10.1016/0168-8278(90)90124-a.
    [47]
    YOUNOSSI ZM, BERNSTEIN D, SHIFFMAN ML, et al. Diagnosis and management of primary biliary cholangitis[J]. Am J Gastroenterol, 2019, 114( 1): 48- 63. DOI: 10.1038/s41395-018-0390-3.
    [48]
    FEJFAR T, VAŇÁSEK T, HŮLEK P. Chronic cholestatic liver diseases-Primary biliary cholangitis and Primary sclerosing cholangitis[J]. Vnitr Lek, 2020, 66( 5): 287- 300.
    [49]
    BLUM HE. Chronic cholestatic liver diseases[J]. J Gastroenterol Hepatol, 2002, 17( Suppl 3): S399- S402. DOI: 10.1046/j.1440-1746.17.s3.34.x.
    [50]
    PADDA MS, SANCHEZ M, AKHTAR AJ, et al. Drug-induced cholestasis[J]. Hepatology, 2011, 53( 4): 1377- 1387. DOI: 10.1002/hep.24229.
    [51]
    TRIVEDI PJ, HIRSCHFIELD GM. Recent advances in clinical practice: Epidemiology of autoimmune liver diseases[J]. Gut, 2021, 70( 10): 1989- 2003. DOI: 10.1136/gutjnl-2020-322362.
    [52]
    LI XY, TANG JT, MAO YM. Incidence and risk factors of drug-induced liver injury[J]. Liver Int, 2022, 42( 9): 1999- 2014. DOI: 10.1111/liv.15262.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2011) PDF downloads(15) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[3590]YesterdayPV[6562]TodayIP[1063]TodayPV[1470]Online[197]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return